DiaMedica Therapeutics to Participate in 10th Annual Craig-Hallum Alpha Select Conference
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that Rick Pauls, President & Chief Executive Officer, will meet with institutional investors at the 10th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 12, 2019, at theSheraton New York Times Square Hotel in New York City.
Interested institutional investors should contact their Craig-Hallum sales representative to schedule a meeting.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neurological disorders. DiaMedica's shares are listed on The Nasdaq Capital Market under the trading symbol "DMAC."
Bioforum, the Data Masters, a leading contract research organization (CRO) focused on the delivery of biometric services and solutions to the global clinical trials industry, today announced the launch of SUBMIT24 in its beta version during Q3 2024,...
Calliditas Therapeutics AB , ("Calliditas") today announced that the global open-label extension (OLE) study to the Phase 3 NefIgArd study showed a treatment response consistent with the NefIgArd study across endpoints of urine protein to creatinine...
CSL Vifor and Travere Therapeutics, Inc., today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the...
Tetra Pharm Technologies and Glysious are pleased to announce a strategic collaboration aimed at developing a ground-breaking transdermal drug delivery system complementing several of Tetra Pharm Technologies' pipeline candidates. The...
